The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.
|Podcasts|May 18, 2022
The Cutaneous Connection: Adherence to Atopic Dermatitis Treatment
Author(s)Linda Stocum, Associate Editor
In this episode, the topics up for discussion include possible technologies to help atopic dermatitis patient adherence with treatment along with new strategies to improve patient experiences at the practice.
Advertisement
Advertisement
Related to this article
Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
3
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
4
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
5